Advertisement

Psychopharmacology

, Volume 220, Issue 3, pp 495–508 | Cite as

Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: Correlations between behavior and neurochemistry

  • Kevin Sean Murnane
  • Shane Alan Perrine
  • Brendan James Finton
  • Matthew Peter Galloway
  • Leonard Lee Howell
  • William Edward Fantegrossi
Original Investigation

Abstract

Rationale

Considerable evidence indicates that amphetamine derivatives can deplete brain monoaminergic neurotransmitters. However, the behavioral and cognitive consequences of neurochemical depletions induced by amphetamines are not well established.

Objectives

In this study, mice were exposed to dosing regimens of 3,4-methylenedioxymethamphetamine (MDMA), methamphetamine (METH), or parachloroamphetamine (PCA) known to deplete the monoamine neurotransmitters dopamine and serotonin, and the effects of these dosing regimens on learning and memory were assessed.

Methods

In the same animals, we determined deficits in learning and memory via passive avoidance (PA) behavior and changes in tissue content of monoamine neurotransmitters and their primary metabolites in the striatum, frontal cortex, cingulate, hippocampus, and amygdala via ex vivo high-pressure liquid chromatography.

Results

Exposure to METH and PCA impaired PA performance and resulted in significant depletions of dopamine, serotonin, and their metabolites in several brain regions. Multiple linear regression analysis revealed that the tissue concentration of dopamine in the anterior striatum was the strongest predictor of PA performance, with an additional significant contribution by the tissue concentration of the serotonin metabolite 5-hydroxyindoleacetic acid in the cingulate. In contrast to the effects of METH and PCA, exposure to MDMA did not deplete anterior striatal dopamine levels or cingulate levels of 5-hydroxyindoleacetic acid, and it did not impair PA performance.

Conclusions

These studies demonstrate that certain amphetamines impair PA performance in mice and that these impairments may be attributable to specific neurochemical depletions.

Keywords

Drug abuse Amphetamine Neurotoxicity Monoamine Mouse Dopamine Learning and memory Behavior Methamphetamine HPLC 

Supplementary material

213_2011_2504_MOESM1_ESM.doc (162 kb)
Supplementary Figure 1 (DOC 161 kb)

References

  1. Achat-Mendes C, Ali SF, Itzhak Y (2005) Differential effects of amphetamines-induced neurotoxicity on appetitive and aversive Pavlovian conditioning in mice. Neuropsychopharmacology 30:1128–1137PubMedCrossRefGoogle Scholar
  2. Achat-Mendes C, Anderson KL, Itzhak Y (2007) Impairment in consolidation of learned place preference following dopaminergic neurotoxicity in mice is ameliorated by N-acetylcysteine but not D1 and D2 dopamine receptor agonists. Neuropsychopharmacology 32:531–541PubMedCrossRefGoogle Scholar
  3. Adriani W, Felici A, Sargolini F, Roullet P, Usiello A, Oliverio A, Mele A (1998) N-methyl-d-aspartate and dopamine receptor involvement in the modulation of locomotor activity and memory processes. Exp Brain Res 123:52–59PubMedCrossRefGoogle Scholar
  4. Ali SF, Newport GD, Holson RR, Slikker W Jr, Bowyer JF (1994) Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. Brain Res 658:33–38PubMedCrossRefGoogle Scholar
  5. Barrionuevo M, Aguirre N, Del Rio JD, Lasheras B (2000) Serotonergic deficits and impaired passive-avoidance learning in rats by MDEA: a comparison with MDMA. Pharmacol Biochem Behav 65:233–240PubMedCrossRefGoogle Scholar
  6. Belcher AM, Feinstein EM, O’Dell SJ, Marshall JF (2008) Methamphetamine influences on recognition memory: comparison of escalating and single-day dosing regimens. Neuropsychopharmacology 33:1453–1463PubMedCrossRefGoogle Scholar
  7. Bolla KI, McCann UD, Ricaurte GA (1998) Memory impairment in abstinent MDMA (“Ecstasy”) users. Neurology 51:1532–1537PubMedGoogle Scholar
  8. Buchert R, Obrocki J, Thomasius R, Vaterlein O, Petersen K, Jenicke L, Bohuslavizki KH, Clausen M (2001) Long-term effects of ‘ecstasy’ abuse on the human brain studied by FDG PET. Nucl Med Commun 22:889–897PubMedCrossRefGoogle Scholar
  9. Colado MI, O’Shea E, Green AR (2004) Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berl) 173:249–263CrossRefGoogle Scholar
  10. Fantegrossi WE, Ciullo JR, Wakabayashi KT, De La Garza R 2nd, Traynor JR, Woods JH (2008) A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience 151:533–543PubMedCrossRefGoogle Scholar
  11. Fuller RW, Hines CW, Mills J (1965) Lowering of brain serotonin level by chloramphetamines. Biochem Pharmacol 14:483–488PubMedCrossRefGoogle Scholar
  12. Fuller RW, Baker JC, Molloy BB (1977) Biological disposition of rigid analogs of amphetamine. J Pharm Sci 66:271–272PubMedCrossRefGoogle Scholar
  13. Gibb JW, Johnson M, Stone D, Hanson GR (1990) MDMA: historical perspectives. Ann N Y Acad Sci 600:601–611, discussion 611–2PubMedCrossRefGoogle Scholar
  14. Gower AJ, Lamberty Y (1993) The aged mouse as a model of cognitive decline with special emphasis on studies in NMRI mice. Behav Brain Res 57:163–173PubMedCrossRefGoogle Scholar
  15. Hanson KL, Luciana M (2004) Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use. Psychol Med 34:229–246PubMedCrossRefGoogle Scholar
  16. Hirata H, Ladenheim B, Rothman RB, Epstein C, Cadet JL (1995) Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals. Brain Res 677:345–347PubMedCrossRefGoogle Scholar
  17. Itzhak Y, Achat-Mendes CN, Ali SF, Anderson KL (2004) Long-lasting behavioral sensitization to psychostimulants following p-chloroamphetamine-induced neurotoxicity in mice. Neuropharmacology 46:74–84PubMedCrossRefGoogle Scholar
  18. Kalechstein AD, Newton TF, Green M (2003) Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci 15:215–220PubMedCrossRefGoogle Scholar
  19. Kalechstein AD, De La Garza R 2nd, Mahoney JJ 3rd, Fantegrossi WE, Newton TF (2007) MDMA use and neurocognition: a meta-analytic review. Psychopharmacology (Berl) 189:531–537CrossRefGoogle Scholar
  20. Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS (2000) Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. Neurology 55:294–296PubMedGoogle Scholar
  21. Kita T, Wagner GC, Nakashima T (2003) Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption. J Pharmacol Sci 92:178–195PubMedCrossRefGoogle Scholar
  22. Krasnova IN, Hodges AB, Ladenheim B, Rhoades R, Phillip CG, Cesena A, Ivanova E, Hohmann CF, Cadet JL (2009) Methamphetamine treatment causes delayed decrease in novelty-induced locomotor activity in mice. Neurosci Res 65:160–165PubMedCrossRefGoogle Scholar
  23. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA (1998) Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings. Lancet 352:1433–1437PubMedCrossRefGoogle Scholar
  24. McCann UD, Peterson SC, Ricaurte GA (2007) The effect of catecholamine depletion by alpha-methyl-para-tyrosine on measures of cognitive performance and sleep in abstinent MDMA users. Neuropsychopharmacology 32:1695–1706PubMedCrossRefGoogle Scholar
  25. McCardle K, Luebbers S, Carter JD, Croft RJ, Stough C (2004) Chronic MDMA (ecstasy) use, cognition and mood. Psychopharmacology (Berl) 173:434–439CrossRefGoogle Scholar
  26. Miller DB, O’Callaghan JP (1995) The role of temperature, stress, and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine. Mol Neurobiol 11:177–192PubMedCrossRefGoogle Scholar
  27. Myhrer T (2003) Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res Brain Res Rev 41:268–287PubMedCrossRefGoogle Scholar
  28. O’Callaghan JP, Miller DB (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741–751PubMedGoogle Scholar
  29. Obrocki J, Schmoldt A, Buchert R, Andresen B, Petersen K, Thomasius R (2002) Specific neurotoxicity of chronic use of ecstasy. Toxicol Lett 127:285–297PubMedCrossRefGoogle Scholar
  30. Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates, 2nd edn. Academic Press, San DiegoGoogle Scholar
  31. Pletscher A, Burkard WP, Bruderer H, Gey KF (1963) Decrease of cerebral 5-hydroxytryptamine and 5-hydroxyindolacetic acid by an arylalkylamine. Life Sci 11:828–833PubMedCrossRefGoogle Scholar
  32. Pletscher A, Bartholini G, Bruderer H, Burkard WP, Gey KF (1964) Chlorinated arylalkylamines affecting the cerebral metabolism of 5-hydroxytryptamine. J Pharmacol Exp Ther 145:344–350PubMedGoogle Scholar
  33. Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W (2001) Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358:1864–1869PubMedCrossRefGoogle Scholar
  34. Renoir T, Paizanis E, Yacoubi ME, Saurini F, Hanoun N, Melfort M, Lesch KP, Hamon M, Lanfumey L (2008) Differential long-term effects of MDMA on the serotoninergic system and hippocampal cell proliferation in 5-HTT knock-out vs. wild-type mice. Int J Neuropsychopharmacol 11:1149–1162PubMedCrossRefGoogle Scholar
  35. Ricaurte GA (1989) Studies of MDMA-induced neurotoxicity in nonhuman primates: a basis for evaluating long-term effects in humans. NIDA Res Monogr 94:306–322PubMedGoogle Scholar
  36. Saadat KS, Elliott JM, Colado MI, Green AR (2006a) The acute and long-term neurotoxic effects of MDMA on marble burying behaviour in mice. J Psychopharmacol 20:264–271PubMedCrossRefGoogle Scholar
  37. Saadat KS, Elliott JM, Green AR, Moran PM (2006b) High-dose MDMA does not result in long-term changes in impulsivity in the rat. Psychopharmacology (Berl) 188:75–83CrossRefGoogle Scholar
  38. Sanders-Bush E, Bushing JA, Sulser F (1975) Long-term effects of p-chloroamphetamine and related drugs on central serotonergic mechanisms. J Pharmacol Exp Ther 192:33–41PubMedGoogle Scholar
  39. Santucci AC, Knott PJ, Haroutunian V (1996) Excessive serotonin release, not depletion, leads to memory impairments in rats. Eur J Pharmacol 295:7–17PubMedCrossRefGoogle Scholar
  40. Schmidt CJ, Levin JA, Lovenberg W (1987) In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol 36:747–755PubMedCrossRefGoogle Scholar
  41. Scott JC, Woods SP, Matt GE, Meyer RA, Heaton RK, Atkinson JH, Grant I (2007) Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol Rev 17:275–297PubMedCrossRefGoogle Scholar
  42. Simon SL, Dean AC, Cordova X, Monterosso JR, London ED (2010) Methamphetamine dependence and neuropsychological functioning: evaluating change during early abstinence. J Stud Alcohol Drugs 71:335–344PubMedGoogle Scholar
  43. Steranka LR, Sanders-Bush E (1980) Long-term effects of continuous exposure to amphetamine on brain dopamine concentration and synaptosomal uptake in mice. Eur J Pharmacol 65:439–443PubMedCrossRefGoogle Scholar
  44. Steranka L, Bessent R, Sanders-Bush E (1977) Reversible and irreversible effects of p-chloroamphetamine on brain serotonin in mice. Commun Psychopharmacol 1:447–454PubMedGoogle Scholar
  45. Stone DM, Hanson GR, Gibb JW (1987) Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats. Neuropharmacology 26:1657–1661PubMedCrossRefGoogle Scholar
  46. Sugimoto Y, Ohkura M, Inoue K, Yamada J (2001) Involvement of serotonergic and dopaminergic mechanisms in hyperthermia induced by a serotonin-releasing drug, p-chloroamphetamine in mice. Eur J Pharmacol 430:265–268PubMedCrossRefGoogle Scholar
  47. Taghzouti K, Simon H, Louilot A, Herman JP, Le Moal M (1985) Behavioral study after local injection of 6-hydroxydopamine into the nucleus accumbens in the rat. Brain Res 344:9–20PubMedCrossRefGoogle Scholar
  48. Timar J, Gyarmati S, Szabo A, Furst S (2003) Behavioural changes in rats treated with a neurotoxic dose regimen of dextrorotatory amphetamine derivatives. Behav Pharmacol 14:199–206PubMedCrossRefGoogle Scholar
  49. Wang X, Baumann MH, Xu H, Rothman RB (2004) 3,4-Methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein. Synapse 53:240–248PubMedCrossRefGoogle Scholar
  50. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699–703PubMedCrossRefGoogle Scholar
  51. Winsauer PJ, McCann UD, Yuan J, Delatte MS, Stevenson MW, Ricaurte GA, Moerschbaecher JM (2002) Effects of fenfluramine, m-CPP and triazolam on repeated-acquisition in squirrel monkeys before and after neurotoxic MDMA administration. Psychopharmacology (Berl) 159:388–396CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Kevin Sean Murnane
    • 1
  • Shane Alan Perrine
    • 5
  • Brendan James Finton
    • 1
    • 2
  • Matthew Peter Galloway
    • 5
    • 6
  • Leonard Lee Howell
    • 1
    • 3
  • William Edward Fantegrossi
    • 4
  1. 1.Division of Neuropharmacology and Neurologic DiseasesYerkes National Primate Research Center, Yerkes Imaging CenterAtlantaUSA
  2. 2.Department of Medical and Clinical PsychologyUniformed Services UniversityBethesdaUSA
  3. 3.Department of Psychiatry and Behavioral SciencesEmory UniversityAtlantaUSA
  4. 4.Department of Pharmacology and Toxicology, College of MedicineUniversity of Arkansas for Medical SciencesLittle RockUSA
  5. 5.Department of Psychiatry and Behavioral NeurosciencesWayne State University School of MedicineDetroitUSA
  6. 6.Department of AnesthesiologyWayne State University School of MedicineDetroitUSA

Personalised recommendations